Jayant A Talwalkar

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial
    Jayant A Talwalkar
    Division of Gastroneterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Dig Dis Sci 51:1985-91. 2006
  2. ncbi Primary sclerosing cholangitis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Inflamm Bowel Dis 11:62-72. 2005
  3. ncbi An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosis
    Jayant A Talwalkar
    Advanced Liver Diseases Study Group, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Med 116:759-66. 2004
  4. ncbi Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Gastroenterol 39:168-71. 2005
  5. ncbi An evidence-based approach to studies in cirrhosis and portal hypertension: medical management of mild to moderate ascites
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 1:474-9. 2003
  6. ncbi Antifibrotic therapies--emerging biomarkers as treatment end points
    Jayant A Talwalkar
    Center for Advanced Imaging Research, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Nat Rev Gastroenterol Hepatol 7:59-61. 2010
  7. ncbi Influence of recent advances in medical management on clinical outcomes of cirrhosis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1501-8. 2005
  8. ncbi Effect of minimal listing criteria on waiting list registration for liver transplantation: a process-outcome analysis
    Jayant A Talwalkar
    Transplant Center, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:431-5. 2003
  9. ncbi Tacrolimus for the treatment of primary sclerosing cholangitis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Liver Int 27:451-3. 2007
  10. ncbi Cost-effectiveness of treating esophageal varices
    Jayant A Talwalkar
    Advanced Liver Diseases Study Group, Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Clin Liver Dis 10:679-89, xi. 2006

Collaborators

Detail Information

Publications61

  1. ncbi Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial
    Jayant A Talwalkar
    Division of Gastroneterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Dig Dis Sci 51:1985-91. 2006
    ..Three of the four patients had drug-related adverse events with fluoxetine. In this study, fluoxetine did not improve fatigue in PBC and was associated with adverse events...
  2. ncbi Primary sclerosing cholangitis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Inflamm Bowel Dis 11:62-72. 2005
    ..Liver transplantation remains the only successful treatment option for patients with advanced liver disease from PSC. A diagnosis of PSC should be considered among individuals with IBD and elevated serum liver biochemical tests...
  3. ncbi An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosis
    Jayant A Talwalkar
    Advanced Liver Diseases Study Group, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Med 116:759-66. 2004
    ..In this article, a number of hypothetical patient-based cases drawn from the authors' experiences are utilized to illustrate these issues...
  4. ncbi Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Gastroenterol 39:168-71. 2005
    ..Mycophenolate mofetil (MMF) is an immunosuppressive medication that inhibits T and B lymphocyte proliferation. The aim of this investigation was to determine the safety and estimated efficacy of MMF in patients with PBC...
  5. ncbi An evidence-based approach to studies in cirrhosis and portal hypertension: medical management of mild to moderate ascites
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 1:474-9. 2003
    ..The evidence-based medicine concepts have been expanded from previous articles, and examples from the hepatology literature have been used...
  6. ncbi Antifibrotic therapies--emerging biomarkers as treatment end points
    Jayant A Talwalkar
    Center for Advanced Imaging Research, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Nat Rev Gastroenterol Hepatol 7:59-61. 2010
    ..This article will attempt to highlight the potential for emerging biomarkers to serve as end points in clinical studies that target salient features of hepatic fibrogenesis...
  7. ncbi Influence of recent advances in medical management on clinical outcomes of cirrhosis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1501-8. 2005
    ....
  8. ncbi Effect of minimal listing criteria on waiting list registration for liver transplantation: a process-outcome analysis
    Jayant A Talwalkar
    Transplant Center, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:431-5. 2003
    ..To determine the level of association between minimal listing criteria (MLC) recognition and outcomes associated with waiting list registration for liver transplantation (LT)...
  9. ncbi Tacrolimus for the treatment of primary sclerosing cholangitis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Liver Int 27:451-3. 2007
    ..Results from a pilot investigation with tacrolimus for primary sclerosing cholangitis (PSC) demonstrated biochemical improvement without excessive drug toxicity. To date, no confirmatory study has been performed...
  10. ncbi Cost-effectiveness of treating esophageal varices
    Jayant A Talwalkar
    Advanced Liver Diseases Study Group, Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Clin Liver Dis 10:679-89, xi. 2006
    ..Recently, several economic analyses have been developed to answer these questions and identify gasps in knowledge. This article provides an overview of results from these studies and explores areas in need of future investigation...
  11. ncbi Medical and economic impact of autoimmune hepatitis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street, S W Rochester, MN 55905, USA
    Clin Liver Dis 6:649-67. 2002
    ..As a result, the ability to plan for disease management strategies in AIH that require the allocation of scarce resources will be feasible...
  12. ncbi Shall we bury the sword? Imaging of hepatic fibrosis
    Jayant A Talwalkar
    Advanced Liver Diseases Study Group, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastroenterology 131:1669-71. 2006
  13. ncbi Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications
    Jayant A Talwalkar
    Advanced Liver Diseases Study Group, Miles and Shirley Fitterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN, USA
    Hepatology 47:332-42. 2008
    ..hepatology 2007.)...
  14. ncbi Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid
    Phunchai Charatcharoenwitthaya
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Dig Dis Sci 55:476-83. 2010
    ..2) was associated with the treatment. Fatigue and health-related quality of life scores during treatment demonstrated a trend toward improvement. Moexipril was not clinically beneficial to PBC patients responding suboptimally to UDCA...
  15. ncbi Mycophenolate mofetil for the treatment of primary sclerosing cholangitis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 SW First Street, Rochester, MN 55905, USA
    Am J Gastroenterol 100:308-12. 2005
    ..In conclusion, MMF does not appear to have clinically important benefits for PSC despite being tolerated by most patients. The results of this pilot study do not support further study of MMF as a single agent in the treatment of PSC...
  16. ncbi Natural history of pruritus in primary biliary cirrhosis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 1:297-302. 2003
    ..No significant risk reduction in developing pruritus with UDCA therapy was observed compared to placebo-treated patients. The long-term administration of rifampin for refractory pruritus is associated with occasional hepatotoxicity...
  17. ncbi Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes
    Marina G Silveira
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 102:1244-50. 2007
    ..Patients with PBC should receive ursodeoxycholic acid (UDCA); the role of and response to additional immunosuppressive therapy are unknown when AIH overlaps PBC...
  18. ncbi A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varices
    Roman E Perri
    Advanced Liver Diseases Study Group, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 47:1587-94. 2008
    ..CONCLUSION: Abdominal CT as the initial screening test for varices could be cost-effective. CT also permits evaluation of extra-luminal pathology that impacts management...
  19. ncbi Octreotide therapy for advanced hepatocellular carcinoma
    Wilco A Slijkhuis
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Gastroenterol 39:333-8. 2005
    ..In conclusion, although occasional patients appear to have stable disease on long-acting octreotide therapy, overall the beneficial response in terms of time to tumor progression and survival is limited...
  20. ncbi Dynamic postprandial hepatic stiffness augmentation assessed with MR elastography in patients with chronic liver disease
    Meng Yin
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    AJR Am J Roentgenol 197:64-70. 2011
    ....
  21. ncbi Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography
    Jun Chen
    Department of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    Radiology 259:749-56. 2011
    ....
  22. ncbi Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension
    Jayant A Talwalkar
    Advanced Liver Diseases Study Group, Department of Gastroenterology and Hepatology, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, MN, USA
    AJR Am J Roentgenol 193:122-7. 2009
    ..The purposes of this study were to determine the feasibility of measuring spleen stiffness with MR elastography and to prospectively test the technique in healthy volunteers and in patients with compensated liver disease...
  23. ncbi Assessment of hepatic fibrosis with magnetic resonance elastography
    Meng Yin
    Department of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Gastroenterol Hepatol 5:1207-1213.e2. 2007
    ....
  24. ncbi Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 97:1191-7. 2002
    ..Applicability of the revised IAHG scoring system, however, remains questionable, as nearly 20% of PBC patients will be classified with probable AIH overlap...
  25. ncbi Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation
    Phunchai Charatcharoenwitthaya
    Miles and Shirley Fitterman Center for Digestive Diseases, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Liver Transpl 13:1236-45. 2007
    ..In this short period of treatment, UDCA was not associated with improved patient and graft survival compared to untreated patients...
  26. ncbi Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy
    Konstantinos N Lazaridis
    Center for Basic Research in Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Gastroenterol 41:494-500. 2007
    ....
  27. ncbi Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence
    Jason T Lewis
    Division of Anatomic Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 31:907-13. 2007
    ..The strong correlation between gallbladder dysplasia/adenocarcinoma and bile duct dysplasia/CC supports the concept of a neoplastic "field effect" along the intrahepatic and extrahepatic biliary tract in PSC...
  28. ncbi Risk factors for mortality after surgery in patients with cirrhosis
    Swee H Teh
    Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterology 132:1261-9. 2007
    ..The aim of this study was to determine the risk factors for postoperative mortality in patients with cirrhosis...
  29. ncbi Noninvasive tools to assess hepatic fibrosis: ready for prime time?
    Paul A Schmeltzer
    Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Gastroenterol Clin North Am 40:507-21. 2011
    ....
  30. ncbi Primary biliary cirrhosis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Lancet 362:53-61. 2003
    ..Despite advances in understanding of the disease, it remains one of the major indications for liver transplantation worldwide...
  31. ncbi "Will all liver transplantation patients eventually die from cancer?"
    William Sanchez
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55901, USA
    J Hepatol 44:13-8. 2006
  32. ncbi Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis
    Jayant A Talwalkar
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 40:39-45. 2004
    ..30 US dollars would be required. In conclusion, MRC has comparable accuracy to ERCP and results in cost savings when used as the initial test strategy for diagnosing PSC...
  33. ncbi Diagnostic evaluation of nonalcoholic fatty liver disease
    Leon A Adams
    Division of Gastroenterology and Hepatology, Mayo Clinic and College of Medicine, Rochester, MN 55905, USA
    J Clin Gastroenterol 40:S34-8. 2006
    ..Clinical features, particularly diabetes, obesity, and older age, can aid in stratifying patients at risk for advanced fibrosis but are not sufficiently accurate to replace liver biopsy...
  34. ncbi Abdominal magnetic resonance elastography
    Meng Yin
    Department of Radiology, Mayo Clinic, Rochester, MN, USA
    Top Magn Reson Imaging 20:79-87. 2009
    ..Steady technical progress in developing practical protocols for applying MRE in the abdomen and the pelvis provides opportunities to explore many other potential applications of this emerging technology...
  35. ncbi MR elastography of liver tumors: preliminary results
    Sudhakar K Venkatesh
    Department of Radiology, Mayo Clinic and Foundation, 200 First St SW, Opus Bldg, Rochester, MN 55905, USA
    AJR Am J Roentgenol 190:1534-40. 2008
    ..The purpose of this study was to evaluate the potential value of MR elastography (MRE) in the characterization of solid liver tumors...
  36. ncbi Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis
    Corlan O Adebajo
    Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Liver Transpl 18:323-31. 2012
    ..The detection of significant fibrosis is more accurate for these patients versus patients whose native liver is chronically infected with HCV...
  37. ncbi Motion - all patients with NASH need to have a liver biopsy: arguments for the motion
    Jayant A Talwalkar
    Mayo Clinic and Foundation, Rochester 55902, USA
    Can J Gastroenterol 16:718-21. 2002
    ..Only histological examination can establish the diagnosis of NASH, grade its severity, determine the prognosis and guide treatment...
  38. ncbi Acute graft-versus-host disease after liver transplantation diagnosed by fluorescent in situ hybridization testing of skin biopsy specimens
    Alexander Meves
    Department of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Am Acad Dermatol 55:642-6. 2006
    ..We conclude that early testing of skin biopsy specimens using fluorescent in situ hybridization in sex-mismatched patients with orthotopic liver transplantation can serve as an early diagnostic tool for graft-versus-host disease...
  39. ncbi Palliative care for patients with end-stage liver disease ineligible for liver transplantation
    William Sanchez
    Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55901, USA
    Gastroenterol Clin North Am 35:201-19. 2006
    ..Medicare provides a hospice benefit for patients with ESLD, and referral to a hospice is appropriate for patients with an expected survival of 6 months or less...
  40. ncbi Diagnosis and staging of hepatocellular carcinoma
    Jayant A Talwalkar
    William J. von Liebig Transplantation Center, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Gastroenterology 127:S126-32. 2004
    ..Additional diagnostic techniques based on cytological advances, genomics, and proteomics are needed for the diagnosis and staging of this highly malignant neoplasm...
  41. ncbi Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C
    Stanley S Liu
    Viral Hepatitis Study Group, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN, USA
    J Clin Gastroenterol 44:e178-85. 2010
    ..The aim of our study was to examine the influence of antidepressant treatment and whether this improves the likelihood of completing therapy...
  42. ncbi Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis
    Jayant A Talwalkar
    Advanced Liver Disease Study Group, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Gastroenterol Hepatol 5:1214-20. 2007
    ..The aims of this study were to perform a systematic review and meta-analysis of diagnostic accuracy studies comparing ultrasound-based transient elastography with liver biopsy for hepatic fibrosis...
  43. ncbi Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels
    Suzette J Bielinski
    Division of Epidemiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 86:606-14. 2011
    ....
  44. ncbi Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment
    Jayant A Talwalkar
    Advanced Liver Diseases Study Group, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 141:1673-9. 2011
    ..We documented the frequency of large spontaneous portosystemic shunts in patients with moderate or severe portopulmonary hypertension (POPH) and determined the association between large shunts and response to treatment...
  45. ncbi Enhancing the role of internal medicine subspecialty societies in defining quality of care
    Jayant A Talwalkar
    Mayo Clinic College of Medicine, USA
    Minn Med 89:42-5. 2006
  46. ncbi Determining the extent of quality health care for hospitalized patients with cirrhosis
    Jayant A Talwalkar
    Advanced Liver Diseases Study Group, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Hepatology 42:492-4. 2005
    ..These results contribute to defining the natural course and prognosis of decompensated HCV-related cirrhosis...
  47. ncbi Celiac disease-associated autoimmune cholangitis
    Robert E Sedlack
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 97:3196-8. 2002
    ..CD should be considered in all patients diagnosed with autoimmune cholangitis as a gluten-free diet may avoid the need for immunosuppressive therapy in affected patients...
  48. ncbi Practice variation in treatment of primary biliary cirrhosis and effect on clinical outcomes
    Jayant A Talwalkar
    Hepatology 47:1428. 2008
  49. ncbi Markov models in primary biliary cirrhosis
    Jayant A Talwalkar
    Gastroenterology 123:1750-1. 2002
  50. ncbi Current and emerging surrogate markers of hepatic fibrosis in primary biliary cirrhosis
    Jayant A Talwalkar
    Liver Int 28:761-3. 2008
  51. ncbi Determining the nature and impact of fatigue after liver transplantation
    Jayant A Talwalkar
    Liver Transpl 12:899-901. 2006
  52. ncbi Prophylaxis with beta blockers as a performance measure of quality health care in cirrhosis
    Jayant A Talwalkar
    Gastroenterology 130:1005-7. 2006
  53. ncbi Functional hepatic imaging and disease recurrence after liver transplantation
    Jayant A Talwalkar
    Liver Transpl 12:1744-6. 2006
  54. ncbi Economic impact of hospitalization for end-stage liver disease
    Jayant A Talwalkar
    Am J Gastroenterol 97:1562; author reply 1562-3. 2002
  55. ncbi Acute graft-versus-host disease after liver transplantation
    M Peter Ghali
    Transplantation 83:365-6. 2007
  56. ncbi Role of computerized image morphometry for assessing noninvasive methods to detect hepatic fibrosis
    Jayant A Talwalkar
    Clin Gastroenterol Hepatol 6:958-9. 2008
  57. ncbi Elastography for detecting hepatic fibrosis: options and considerations
    Jayant A Talwalkar
    Gastroenterology 135:299-302. 2008
  58. ncbi Analysis of factors that predict alcohol relapse following liver transplantation
    Sameer Jauhar
    University of Glasgow, Scotland, UK
    Liver Transpl 10:408-11. 2004
    ..03). Further prospective studies are needed to examine this association in greater detail to provide targeted treatment for alcoholism both before and after liver transplantation...
  59. ncbi Polluting the pathogenesis of primary biliary cirrhosis
    Jayant A Talwalkar
    Hepatology 43:398-400. 2006
  60. ncbi Methodologic issues with transfer of ultrasound-based transient elastography into clinical practice
    Jayant A Talwalkar
    J Hepatol 47:301-2. 2007
  61. ncbi Risk of lymphoma in primary biliary cirrhosis
    Chakri Panjala
    Division of Gastroenterology Hepatology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA
    Clin Gastroenterol Hepatol 5:761-4. 2007
    ..Therefore, we sought to describe the frequency, clinical spectrum, and outcomes among patients with PBC and a concomitant diagnosis of lymphoma...